Currently browsing tag

roche

Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint

Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma, over current drug Rituxan in a phase III GOYA study, Roche said on Monday. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma.

Roche therapy helps 24 percent of untreated bladder cancer patients: study

A newly approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday. Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become the first option therapy of choice for patients with metastatic bladder cancer, according to a researcher leading the study. Known chemically as atezolizumab, Tecentriq last month won U.S. approval for bladder cancer that had progressed following chemotherapy, becoming the first new drug for the disease in 30 years.

Diagnostics, Tamiflu help Roche full-year sales beat poll

ZURICH (Reuters) – Swiss drugmaker Roche expects sales and profits to grow at a similar pace to last year, after a strong performance by its diagnostics unit and flu drug Tamiflu helped full-year sales beat expectations. Stripping out the impact of currency fluctuations, the world's largest maker of cancer drugs forecast 2015 sales to grow in the low-to-mid single digit range, while core earnings per share (EPS) should grow more than sales. Full-year sales rose 1 percent to 47.5 billion Swiss francs ($52.5 billion), generating flat core earnings per share (EPS) of 14.29 Swiss francs. …